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AbstrAct
Heart failure (HF) is a global health problem inherent in an aging population with coexisting cardiovascular 
diseases. Based on data from the Polish National Health Fund (Polish, Narodowy Fundusz Zdrowia), 
approximately 1.2 million people in Poland currently suffer from HF, and 140 000 of them die annually. 
Recently, Poland was ranked fifth among the European Union countries regarding the number of patients 
with diagnosed HF and first in terms of the number of HF hospitalizations (547 per 100 000 population) 
among 34 countries associated in the Organization for Economic Cooperation and Development. In recent 
years, a significant progress has been made in the diagnosis and treatment of HF with reduced left 
ventricular ejection fraction (HFrEF), which has resulted in a reduction in cardiovascular and total mortality. 
Despite these advantages, 5-year survival in the course of HF is still worse than that observed in some 
types of cancer, both in the populations of men and women. Hence, the search for drugs improving 
the prognosis in this group of patients is still ongoing. Sodium-glucose cotransporter 2 inhibitors represent 
a new group of drugs that will undoubtedly be a milestone in the treatment of patients with HFrEF. This 
expert opinion covers the history of dapagliflozin, which, from a drug dedicated to the treatment of type 
2 diabetes, has become one of the most effective drugs improving prognosis and quality of life as well 
as reducing the number of hospitalizations in patients with HF. This document presents the opinion from 
the experts of the Heart Failure Working Group of the Polish Cardiac Society on the most relevant studies 
on dapagliflozin and indications for its use.
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inhibitors of the renin–angiotensin–aldoste-
rone system, including angiotensin-converting 
enzyme inhibitors (ACEIs) and angiotensin re-
ceptor blockers (ARBs), have been used as triple 
therapy for HFrEF over the past years, partial-
ly changing the course of the disease. Despite 
that, 5-year survival in patients with HF is still 
worse than that observed in some types of cancer 
(except for lung cancer), in both men and wom-
en.13 Therefore, there is still a need for new, ef-
fective therapies for HF. Patients with HF con-
stitute a very difficult-to-treat population ow-
ing to the frequent presence of comorbidities. 
According to the European Society of Cardiolo-
gy Heart Failure Pilot Study database, as many 
as 74% of patients with HF have at least one co-
morbid disease, and 20% to 25% have 5 comor-
bidities.14 According to the available data, coro-
nary artery disease is one of the major reasons 
of HFrEF. The most common comorbidities in-
clude arterial hypertension, chronic obstructive 
pulmonary disease, renal failure, and anemia.15 
Moreover, type 2 diabetes (T2D) is also often 
associated with HF. Its prevalence in patients 
with HF ranges from 12% to 30% in the gener-
al population and from 15% to 47% in clinical 
trials.16 In patients with T2D, HF develops about 
2.5-fold more frequently than in those without 
T2D, and T2D develops more often in patients 
with HF than in those without HF. In patients 
with T2D, the development of HF represents 
one of the most common early cardiovascular 
complications.16,17
Among patients with HF in Poland, fre-
quent hospitalizations pose the biggest prob-
lem; the most common reason for hospitaliza-
tion, particularly in people over 65 years of 
age, is cardiovascular decompensation, indi-
cating disease progression.6 Exacerbations of 
HF are significantly life-threatening and lead to 
a gradual deterioration of health and, most im-
portantly, shortening of life.18 In Poland, more 
than half of patients with HF are readmitted to 
the hospital, and every fourth patient returns 
to the hospital within 30 days after discharge.6 
As many as 11% of patients die within 1 year of 
hospitalization due to cardiovascular decom-
pensation.6,18 The results of groundbreaking re-
search on HF have recently been published and 
showed a reduction in mortality and the fre-
quency of hospitalization. They concern 2 new 
groups of drugs—angiotensin receptor–nepri-
lysin inhibitors (ARNIs), represented by sacu-
bitril / valsartan; and sodium-glucose cotrans-
porter 2 (SGLT-2) inhibitors (flozins), represent-
ed by dapagliflozin, empagliflozin, and cana-
gliflozin. Previous large randomized clinical tri-
als on the use of SGLT-2 inhibitors in patients 
with T2D have reported a reduction in cardio-
vascular risk, including a decrease in the num-
ber of hospitalizations for HF19 -21; however, HF 
was not an inclusion criterion in those studies. 
epidemiology of heart failure Heart failure 
(HF) is a health problem characteristic of an ag-
ing population burdened with cardiovascular 
diseases.1 According to epidemiological data, 
HF affects about 64 million people worldwide,2 
and this number will undoubtedly increase due 
to increasing life expectancy.3 The risk of devel-
oping HF increases with age and was assessed 
as follows: 28.5% for women and 33% for men 
over 55 years of age.4 Heart failure is associated 
with poor prognosis, as evidenced by high rates 
of hospitalization and mortality (about 40% of 
patients die within 5 years after their first hos-
pitalization for HF).5,6 In Poland, as many as 53% 
of patients with HF are readmitted to the hospi-
tal, and every fourth patient requires rehospital-
ization within 30 days of discharge.5,6 Although 
cardiovascular mortality has decreased in recent 
years, deaths due to HF have not.7,8 Forecasts 
for the coming years indicate that the number 
of people affected by HF will increase by nearly 
25%, which will cause a significant societal bur-
den.9 Therefore, HF is now seen as an epidemic 
of the 21st century.
According to our studies based on data 
from the Polish National Health Fund (Polish, 
Narodowy Fundusz Zdrowia [NFZ]), about 1.2 
million people have HF in Poland, of whom 140 
000 die every year. In 2017, Poland was ranked 
fifth among the European Union countries in 
terms of the number of patients with HF (1130 
cases per 100 000 population) and first among 
34 countries of the Organization for Economic 
Co-operation and Development (OECD) in terms 
of the number of hospitalizations due to HF 
(547 cases per 100 000 population).10,11 The cur-
rent situation regarding HF in Poland was most 
comprehensively presented by the Ministry of 
Health in the report on HF (prepared as part of 
the Health Needs Maps—Database of System-
ic and Implementation Analysis project), based 
on data from NFZ (2009–2018) and Ministry of 
Digital Affairs (2013–2018).12
Based on that analysis, we know that 2 327 399 
people were treated for HF in Poland in the years 
2009 to 2018. That population was dominat-
ed by women (constituting 56.3%). A gradual 
11.9% increase in prevalence was observed from 
1 122 877 cases (2890 per 100 000 population) in 
2013 to 1 242 129 cases (3233 per 100 000 pop-
ulation) in 2018. This increase was most visible 
in women and patients with the disease of isch-
emic etiology.
Unmet needs in the treatment of patients 
with heart failure In recent years, a signif-
icant progress has been made in the diagno-
sis and treatment of patients with HF with re-
duced left ventricular ejection fraction (HFrEF), 
which has resulted in a reduction in cardiovas-
cular and total mortality. β-Blockers, miner-
alocorticoid receptor antagonists (MRAs), and 
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glucotoxicity could have a protective effect on 
pancreatic β cells.25
The benefits of using SGLT-2 inhibitors are not 
limited to their effects on glucose reabsorption. 
Dapagliflozin also reduces sodium reabsorption 
and increases its delivery to the macula densa, 
which regulates afferent arteriole tone through 
the tubuloglomerular feedback. The nephropro-
tective effect resulting from the contraction of 
the renal afferent arterioles reduces intraglo-
merular hyperfiltration and excretion of uri-
nary albumin. The cardiovascular effect includes 
improved hemodynamics and results from in-
creased osmotic diuresis, decreased plasma vol-
ume, and decreased blood pressure, which leads 
to lower left ventricular preload and afterload.26 
Another relevant factor is the beneficial effect 
on the energy of the cardiac muscle. SGLT-2 in-
hibitors increase the production of ketone bod-
ies and their use in the heart, which improves 
the energy metabolism of the cardiac muscle and 
reduces the risk of HF development and recur-
rence.27 Unfavorable remodeling of the heart is 
also inhibited.28
Recently, studies of patients with HFrEF with-
out T2D (DAPA-HF and EMPEROR-Reduced) 
have been completed. However, studies are still 
ongoing in patients with HF with preserved ejec-
tion fraction without T2D (EMPEROR-Preserved 
and DELIVER [Dapagliflozin Evaluation to Im-
prove the Lives of Patients with Preserved Ejec-
tion Fraction Heart Failure]).
As outlined above, the DAPA-HF study was 
the first major clinical trial to analyze patients 
with HF without T2D. In that study, dapa-
gliflozin significantly reduced the risk of car-
diovascular death and hospitalization due to HF. 
This effect was equally evident both in patients 
with T2D and those without concomitant disor-
ders of carbohydrate metabolism. Patients tak-
ing dapagliflozin had less severe HF symptoms 
than those taking placebo, which translated into 
a better quality of life, as assessed by the Kan-
sas City Cardiomyopathy Questionnaire (KCCQ).
european society of cardiology / european As-
sociation for the study of diabetes guidelines 
on the use of SGLT-2 inhibitors in the treat-
ment of type 2 diabetes In 2019, the new 
European Society of Cardiology guidelines for 
the management of diabetes, prediabetes, and 
cardiovascular diseases were developed in co-
operation with the European Association for 
the Study of Diabetes.29 The presented infor-
mation indicated the extremely important role 
of SGLT-2 inhibitors in patients with T2D and 
cardiovascular diseases, clearly emphasizing 
the paradigm shift in the treatment of this group 
of patients. The role of SGLT-2 inhibitors in pa-
tients with T2D and cardiovascular disease was 
analyzed based on 4 large cardiovascular out-
come trials (CVOTs): EMPA-REG OUTCOME,19 
In the DAPA-HF (Dapagliflozin and Prevention 
of Adverse Outcomes in Heart Failure) study, 
the results of which were announced at the Eu-
ropean Congress of Cardiology in Paris on Sep-
tember 1, 2019 and simultaneously published in 
the New England Journal of Medicine, for the first 
time, the attention was focused on patients 
with HF, regardless of whether they were diag-
nosed with T2D or not. In that study, SGLT-2 
inhibitor treatment (dapagliflozin) prevented 
relapses and exacerbations of HF and reduced 
cardiovascular mortality.2 2 It is also interest-
ing that the observed benefits of dapagliflozin 
were independent of the presence of T2D. In 
the context of those pioneering results, we are 
witnessing a breakthrough in the treatment of 
HF. In the EMPEROR-Reduced (Empagliflozin 
Outcome Trial in Patients with Chronic Heart 
Failure with Reduced Ejection Fraction) study, 
which compared the effects of empagliflozin 
in patients with HFrEF regardless of the pres-
ence of T2D, empagliflozin was shown to de-
crease the number of cardiovascular deaths or 
HF hospitalizations (primary endpoint) by 25% 
and reduce the number of the first and subse-
quent hospitalizations for HF (secondary end-
point) by 30%.2 3
Premises for the use of SGLT-2 inhibitors in 
heart failure SGLT-2 inhibitors constitute 
a new group of drugs that were initially dedicat-
ed to treat patients with T2D. However, recent 
large, randomized clinical trials—particularly 
those with dapagliflozin or empagliflozin—have 
revealed their great value in reducing cardio-
vascular complications, particularly associat-
ed with HF not only in patients with coexisting 
T2D (DECLARE-TIMI 58 [Multicenter Trial to 
Evaluate the Effect of Dapagliflozin on the Inci-
dence of Cardiovascular Events] and EMPA-REG 
OUTCOME [Empagliflozin Cardiovascular Out-
come Event Trial in Type 2 Diabetes Mellitus 
Patients] studies) but also in those with HFrEF 
regardless of T2D diagnosis (the DAPA-HF and 
EMPEROR-Reduced studies).
The complex and multidirectional mechanism 
of action of these drugs has a beneficial effect 
on both the control of T2D and the reduction of 
cardiovascular complications. SGLT-2, which is 
present in the proximal renal tubules, is respon-
sible for most of the reabsorption of filtered glu-
cose from the lumen of the tubule. By inhibiting 
SGLT-2, dapagliflozin reduces glucose reabsorp-
tion and lowers the renal glucose threshold, thus 
increasing urinary glucose excretion.24 This effect 
is independent of insulin (both in terms of its 
secretion and its action) and—very important-
ly—is achieved without the risk of hypoglycemia. 
Reducing glucose reabsorption, and thus increas-
ing its excretion with urine, favors a negative en-
ergy balance. This results in weight loss and im-
proves insulin sensitivity, and the reduction in 
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dapagliflozin significantly reduced the com-
posite endpoint (incidence of cardiovascular 
deaths and the number of HF hospitalizations), 
although it did not lower the incidence of ma-
jor adverse cardiovascular events defined as car-
diovascular mortality, myocardial infarction, 
and stroke.
The analysis of the DECLARE-TIMI 58 study 
by Kato et al31 provided further evidence of clin-
ical benefits, particularly in patients with T2D 
and coexisting HF. Kato et al31 assessed the ef-
fect of dapagliflozin added to standard pharma-
cological treatment in patients with HFrEF (de-
fined as left ventricular ejection fraction below 
45%). The effect of dapagliflozin treatment on 
the frequency of renal events (ie, deterioration 
of eGFR by more than 40% and the occurrence 
of end-stage renal disease or death due to renal 
causes) was also assessed.31 There was a signif-
icant reduction in the primary composite end-
point (cardiovascular death or hospitalization for 
HF) in patients with HFrEF treated with dapa-
gliflozin versus placebo. Although the effect of 
dapagliflozin on the incidence of hospitaliza-
tions for HF was consistent in patients with or 
without HFrEF, a significantly greater decrease 
in cardiovascular deaths was observed in pa-
tients with HFrEF. A reduced risk of all-cause 
mortality was also observed with dapagliflozin 
treatment in patients with HFrEF compared with 
those without HFrEF. In patients with HFrEF, 
the benefits of dapagliflozin in reducing car-
diovascular deaths or hospitalizations for HF 
appeared early and were sustained throughout 
the study.
Another benefit of dapagliflozin in the DE-
CLARE-TIMI 58 study was the improvement of 
kidney function. Dapagliflozin treatment result-
ed in a reduction in the incidence of combined 
events including a sustained decline in eGFR, 
development of end-stage renal disease, renal 
death, or cardiovascular death. The difference 
between groups in favor of dapagliflozin was ob-
served owing to a reduction in renal events (ie, 
sustained decline in eGFR, end-stage renal dis-
ease, and renal death). In addition, dapagliflozin 
decreased the incidence of new cases of persis-
tent albuminuria and led to a reduction in mac-
roalbuminuria compared with placebo.
the dAPA-HF study and subgroup analysis 
The results of the DECLARE-TIMI 58 study 
were one of the reasons for the search for fur-
ther evidence of the beneficial effect of dapa-
gliflozin on reducing cardiovascular mortali-
ty in patients with HF without diagnosed T2D. 
The randomized, double-blind, placebo-con-
trolled DAPA-HF study assessed the efficacy and 
safety of dapagliflozin versus placebo (added to 
standard treatment) in patients with HFrEF.2 2 
The study included patients older than 18 years 
of age diagnosed with HFrEF (lasting for at least 
CANVAS (Canagliflozin Cardiovascular As-
sessment Study),20 DECLARE-TIMI 58,21 and 
CREDENCE (Evaluation of the Effects of Cana-
gliflozin on Renal and Cardiovascular Outcomes 
in Participants with Diabetic Nephropathy).30 
Those were the first studies to assess the effect 
of this class of drugs in T2D, not only in terms 
of metabolic benefits but also reduction of car-
diovascular complications. Those studies were 
performed in diverse populations. Almost all pa-
tients in the EMPA-REG OUTCOME study19 had 
cardiovascular disease, whereas only 40% of in-
dividuals in the DECLARE-TIMI 58 study had 
diagnosed cardiovascular disease,21 with the re-
maining 60% of patients having at least one of 
the 3 risk factors (smoking, hypertension, and 
hyperlipidemia). For the first time in the his-
tory of T2D studies, we have data from sever-
al CVOTs indicating a reduction in cardiovas-
cular complications following the use of hypo-
glycemic drugs in patients with diagnosed car-
diovascular diseases and those at high or very 
high cardiovascular risk. Based on the results 
of the abovementioned large randomized tri-
als, the authors of the guidelines recommend 
(class IA) the use of SGLT-2 inhibitors (dapa-
gliflozin, empagliflozin, and canagliflozin) to 
reduce the risk of HF in patients with T2D who 
either have cardiovascular disease or are at high 
or very high cardiovascular risk. In people with 
high or very high cardiovascular risk or multi-
ple cardiovascular risk factors, the recommen-
dation is to start T2D treatment with SGLT-2 or 
glucagon-like peptide 1 inhibitors as monother-
apy and to add metformin as second-line treat-
ment if this is ineffective. When a patient with 
T2D and cardiovascular risk factors is treated 
with metformin, adding an SGLT-2 inhibitor is 
recommended to reduce the risk of cardiovas-
cular events.29
Of note, at the time the abovementioned 
guidelines were developed, the results of the DA-
PA-HF study were not available yet. That study 
examined the effect of dapagliflozin in patients 
diagnosed with HFrEF, regardless of the pres-
ence of carbohydrate metabolism disorders.
The DECLARE-TIMI 58 study and its subanalysess 
The DECLARE-TIMI 58 study2 1 evaluated pa-
tients at 40 years of age and older who were di-
agnosed with T2D and had glycated hemoglo-
bin (HbA1c) levels in the range of 6.5% to 12%, 
an estimated glomerular filtration rate (eGFR) 
greater than or equal to 60 ml/min/1.73 m2, and 
diagnosed cardiovascular disease or cardiovas-
cular risk factors. Patients were randomized 
to receive dapagliflozin 10 mg daily or placebo. 
The authors of the study emphasized a good con-
trol of other cardiovascular risk factors—ie, ap-
propriate mean values of both blood pressure 
and low-density lipoprotein cholesterol. Dur-
ing over 4 years of follow-up, treatment with 
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The results obtained in patients with T2D were 
similar to those of patients without. The positive 
effects of dapagliflozin on the reduction of car-
diovascular deaths and the risk of HF worsening, 
as compared with placebo, were visible by day 28 
of therapy and did not depend on the HF treat-
ment used.34,35 The benefits of dapagliflozin were 
also similar regardless of left ventricular ejection 
fraction. The subgroup analysis also showed that 
patients with HF and a lower functional NYHA 
class (II) benefit more than patients with more 
severe symptoms (NYHA class III to IV). There-
fore, treatment with dapagliflozin in a patient 
with HFrEF should be initiated early, prefera-
bly before discharge from the hospital or at an 
outpatient follow-up visit immediately after 
discharge following hospitalization due to HF 
exacerbation.
The DAPA-HF study was the first to include 
patients with impaired renal function (ie, eGFR 
of 30 to 60 ml/min/1.73 m2). Despite the ini-
tial increase in creatinine levels observed dur-
ing the study in both dapagliflozin and placebo 
groups, the effect of the study drug was favor-
able at further follow-up in patients with both 
normal and impaired eGFRs.
The DAPA-CKD (A Study to Evaluate the Ef-
fect of Dapagliflozin on Renal Outcomes and Car-
diovascular Mortality in Patients With Chron-
ic Kidney Disease) study has recently been com-
pleted.36 It was the first clinical trial to evaluate 
the benefits and risks of SGLT-2 inhibitor use 
in patients with various stages of chronic kid-
ney disease, both with T2D and without carbo-
hydrate metabolism disorders. In March 2020, 
the DAPA-CKD study was terminated prema-
turely following the recommendation of the in-
dependent monitoring committee. The decision 
to terminate the study prematurely was made af-
ter a routine efficacy and safety evaluation that 
demonstrated the benefit of dapagliflozin ear-
lier than assumed in the study protocol. In July 
2020, it was reported that treatment with dapa-
gliflozin was associated with a significant reduc-
tion in the primary composite endpoint, which 
included worsening of renal function (≥50%), de-
velopment of end-stage renal disease, and death 
in adult patients with chronic kidney disease 
regardless of the presence of T2D. In addition, 
a beneficial effect was achieved in all secondary 
endpoints, including all-cause death. The safe-
ty and tolerability profile of dapagliflozin was 
consistent with previously published data from 
other clinical trials.36,37
Safety of dapagliflozin Recent large, interna-
tional, randomized studies on the use of dapa-
gliflozin have revealed the advantages of this 
drug in reducing the incidence of cardiovas-
cular complications in patients with T2D (the 
DECLARE-TIMI 58 study),2 1 as well as in pa-
tients with HFrEF regardless of coexisting T2D 
2 months) with New York Heart Association 
(NYHA) functional class II to IV symptoms 
during the optimal target pharmacological and 
interventional treatment (eg, if they were eli-
gible for implantation of a cardioverter-defi-
brillator or cardiac resynchronization thera-
py).2 2, 32 Pharmacotherapy, in line with the cur-
rent guidelines for the management of HF, was 
based on ACEIs / ARBs or sacubitril / valsartan 
and a β-blocker and / or MRA, consisting of in-
dividualized, stable (for at least 4 weeks) drug 
doses (except for symptom-dependent diuretics). 
The DAPA-HF inclusion criteria also included el-
evated levels of N-terminal fragment of the pro-
hormone brain natriuretic peptide (≥600 pg/ml 
or ≥400 pg/ml if the patient had an episode of 
decompensation due to HF in the year before 
enrollment, or ≥900 pg/ml if the patient had 
coexisting atrial fibrillation or atrial flutter). 
For patients with T2D (about 42% of enrolled 
patients and an additional 3% diagnosed dur-
ing the study), antidiabetic drugs were modi-
fied as needed (eg, reducing insulin and sulfo-
nylurea doses to avoid hypoglycemic episodes), 
particularly in patients with HbA1c below 7%. 
For the first time in studies with dapagliflozin, 
patients with chronic kidney disease (ie, with 
an eGFR of 30 to 60 ml/min/1.73 m2) were in-
cluded. Patients were then randomized (1:1) to 
receive dapagliflozin orally at a dose of 10 mg 
once daily or placebo.
The primary endpoint of the study was the time 
to the composite endpoint, which included cardio-
vascular death, hospitalization for HF, or an ur-
gent visit for HF. The secondary endpoints were 
as follows: cardiovascular mortality or hospital-
ization for HF, the total number of hospitaliza-
tions (first and subsequent) for HF and cardiovas-
cular deaths, improvement in the quality of life 
based on the change from baseline in the KCCQ 
questionnaire after 8 months of follow-up,33 wors-
ening of renal function (ie, persistent decline in 
eGFR by ≥50% or end-stage renal disease defined 
as persistent eGFR decline <15 ml/min/1.73 m2, 
chronic renal dialysis, or kidney transplant) or 
renal death, and death from any cause. The final 
analysis included 4744 patients who were fol-
lowed up for a median of 18 months.
The DAPA-HF study showed: a 26% relative 
reduction in the primary composite endpoint 
(P <0.0001), a 18% reduction in the relative risk 
of cardiovascular death, a 30% reduction in 
the relative risk of worsening / hospitalization 
for HF, a 17% reduction in the relative risk of 
death from any cause, improvement in the qual-
ity of life and lower intensity of HF symptoms 
based on the results of the KCCQ questionnaire 
at 8 months compared with baseline. In addi-
tion, the safety of dapagliflozin was similar to 
placebo in terms of its effects on volume deple-
tion, renal dysfunction, and hypoglycemia, re-
gardless of the presence of T2D.
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not provide adequate glycemic control despite 
optimal insulin therapy (dapagliflozin 5 mg)
•	 in adults, to treat symptomatic HFrEF
In HFrEF, the recommended dose is 10 mg of 
dapagliflozin once daily in combination with 
other medications for HF. No dose adjustment 
is necessary for patients with renal impairment. 
However, experience with dapagliflozin for 
the treatment of HFrEF in patients with severe 
renal impairment (eGFR <30 ml/min/1.73 m2) 
is limited, as well as the experience in patients 
with NYHA class IV. Dapagliflozin is the first 
flozin approved for use in adults with HFrEF.
Use of dapagliflozin in the treatment of heart 
failure: patient population The DAPA-HF tri-
al was a groundbreaking study that demonstrat-
ed the efficacy of SGLT-2 inhibitors for improving 
the prognosis of patients with HFrEF. The results 
of the DAPA-HF study are the basis for the use of 
dapagliflozin in a wide population—not only in 
patients with T2D and HFrEF but also in those 
with HFrEF without T2D.
Currently, over 5 years have passed since 
the  publication of the  recent guidelines for 
the diagnosis and treatment of acute and chronic 
HF. Since then, the results of new clinical trials 
on SGLT-2 inhibitors have appeared, expanding 
our knowledge about their use in various groups 
of patients, including those with HF. Therefore, 
experts from the European Heart Failure Asso-
ciation have recently published a position paper 
on the use of SGLT-2 inhibitors in HFrEF.40 Based 
on the available evidence, SGLT-2 inhibitors (em-
pagliflozin, canagliflozin, and dapagliflozin) may 
be recommended to reduce the risk of hospital-
ization for HF in patients with T2D and estab-
lished cardiovascular disease or who are at high 
cardiovascular risk. Importantly, this position 
paper did not include the recently published DA-
PA-HF (dapagliflozin) and EMPEROR-Reduced 
(empagliflozin) studies. The results of the recent 
CVOTs with antidiabetic drugs have enriched 
our therapeutic knowledge and led to changes in 
both clinical guidelines and drug registrations. 
SGLT-2 inhibitors are a new class of drugs with 
a breakthrough significance in the treatment of 
patients with HF. The collected data will allow 
them to be placed high in the hierarchy of drugs 
that alter the natural course of HF.
Practical guidelines for the use of dapa-
gliflozin Recent studies have indicated that 
SGLT-2 inhibitors will be one of the main groups 
of drugs used in patients with HFrEF. So far, 
dapagliflozin (used in addition to ARNIs, ACEIs 
or ARBs, MRAs, and β-blockers) is the only 
SLGT-2 inhibitor that has proven effective in 
reducing mortality in patients with HFrEF. Sum-
marizing the data presented above, let us outline 
some practical, clinical comments on the use of 
dapagliflozin in patients with HFrEF.
(the DAPA-HF study).2 2 Apart from its efficacy, 
the safety profile of dapagliflozin presented in 
both publications is crucial.
The studies showed that dapagliflozin is a safe 
drug. This is indicated by the rarity of adverse 
events (AEs) leading to treatment discontin-
uation. The most common AEs included mild-
to-moderate fungal infections of the external 
genitourinary organs, which do not require 
discontinuation of SGLT-2 inhibitor treatment. 
The symptoms disappear following treatment 
with a topical antifungal agent or a single dose 
of an antifungal drug. In the DAPA-HF study, 14 
patients (0.6%) in the dapagliflozin group and 
17 (0.7%) in the placebo group had a serious uri-
nary tract infection. According to the results of 
the available studies, the risk of urinary tract 
infection is not increased with SGLT-2 inhibi-
tor therapy and should not raise concerns about 
the implementation of such treatment.
During SGLT-2 inhibitor therapy, osmotic 
diuresis and natriuresis increase, so patients 
should be alerted to the need to drink more flu-
ids. If used, the doses of diuretics (particularly 
loop diuretics) should be appropriately adjusted. 
The risk of developing orthostatic hypotension 
is increased in elderly patients taking SLGT-2 in-
hibitors. Major hypoglycemic events in the DA-
PA-HF study were observed in 4 patients (0.2%) 
in the dapagliflozin group and 4 (0.2%) in the 
placebo group, all of whom had T2D. In both DE-
CLARE-TIMI 58 and DAPA-HF studies, the in-
cidence of AEs related to amputation, fracture, 
hypovolemia, and renal dysfunction was similar 
between the dapagliflozin and placebo groups.
Euglycemic diabetic ketoacidosis could be 
a rare complication of SGLT-2 inhibitor use in 
patients with T2D. Therefore, patients should 
be educated about the need to see a physician 
in case of polyuria, severe nausea and / or vom-
iting, abdominal pain, severe thirst, and rap-
id and deep breaths combined with a “sweet,” 
fruity smell of the breath—in these cases, treat-
ment with SGLT-2 inhibitors should be discon-
tinued after immediate medical consultation. 
These drugs should also be temporarily discon-
tinued during fasting periods (eg, before sur-
gery). Alcohol misuse and ketogenic diets are 
contraindicated.
According to the Summary of Product Char-
acteristics currently valid in Europe,38,39 dapa-
gliflozin is indicated:
•	 in adult patients for the treatment of inade-
quately controlled T2D, as an additional thera-
py to diet and exercise, either alone, in the ab-
sence of metformin tolerance, or in combi-
nation with other medicinal products used 
to treat T2D
•	 in the treatment of insufficiently controlled 
type 1 diabetes as an adjunct to insulin in pa-
tients with a body mass index greater than or 
equal to 27 kg/m2, when insulin alone does 
E X P E R T  O P I N I O N  A N D  P O S I T I O N  P A P E R   Dapagliflozin in heart failure 369
honoraria from AstraZeneca and Boehringer Ingelheim. PRo received lecture hon-
oraria from AstraZeneca and Boehringer Ingelheim. Other authors declare no con-
flict of interest.
Open access This is an Open Access article distributed under the terms 
of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 In-
ternational License (CC BY-NC-ND 4.0), allowing third parties to download ar-
ticles and share them with others, provided the original work is properly cited, 
not changed in any way, distributed under the same license, and used for non-
commercial purposes only. For commercial use, please contact the journal office 
at kardiologiapolska@ptkardio.pl.
HOw tO cite Nessler J, Siniarski A, Leszek P, et al. Expert opinion of the Heart 
Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in 
the treatment of heart failure with reduced ejection fraction. Kardiol Pol. 2021; 79: 
363-370. doi:10.33963/KP.15859
RefeRences
1  World Health Organization. The World Health Report 2008. Primary Health 
Care. http://www.who.int/whr/2008/whr08_en.pdf. Accessed September 9, 2020.
2  GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Glob-
al, regional, and national incidence, prevalence, and years lived with disability for 
328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for 
the Global Burden of Disease Study 2016. Lancet. 2017; 390: 1211-1259.
3  Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statis-
tics–2018 update: a report from the American Heart Association. Circulation. 2018; 
137: e67-e492.
4  Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart fail-
ure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart fail-
ure: the Rotterdam Study. Eur Heart J. 2004; 25: 1614-1619.
5  Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from 
the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008; 101: 1016-1022.
6  Nessler J, Kozierkiewicz A, Gackowski A, et al. Comprehensive Heart Failure Care 
pilot study: starting point and expected developments. Kardiol Pol. 2019; 77: 994-999.
7  Cheng YJ, Imperatore G, Geiss LS, et al. Trends and disparities in cardiovascu-
lar mortality among US adults with and without self-reported diabetes, 1988–2015. 
Diabetes Care. 2018; 41: 2306-23015.
8  Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Pro-
gramme: regional differences and 1‐year follow‐up results of the Heart Failure Pi-
lot Survey (ESC‐HF Pilot). Eur J Heart Fail. 2013; 15: 808-817.
9  Straburzyńska-Migaj E, Nessler J, Gackowski A. 2016 Report on heart fail-
ure in Poland – information materials of the Polish Cardiac Society. https://www.
niewydolnosc-serca.pl/barometr.pdf. Accessed February 23, 2021.
10  OECD. Health at a Glance 2017: OECD Indicators. Paris: OECD Publishing. 
2017. https://doi.org/10.1787/health_glance-2017-en. Accessed February 23, 2021.
11  OECD. Health at a Glance 2019: OECD Indicators. Paris: OECD Publishing. 
2019. https://doi.org/10.1787/4dd50c09-en. Accessed February 23, 2021.
12  Polish Ministry of Health. Ministerstwo Zdrowia. Maps of health needs [in 
Polish]. http://mpz.mz.gov.pl/mapy-kardiologiczne/#tab-2018. Accessed Sep-
tember 15, 2020.
13  Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse outcomes 
in heart failure than in cancer? A primary care-based cohort study with 10-year fol-
low-up in Scotland. Eur J Heart Fail. 2017; 19: 1095-1104.
14  Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with pre-
served ejection fraction. Nat Rev Cardiol. 2017; 14: 591-602.
15  Chamberlain AM, Sauver JLS, Gerber Y, et al. Multimorbidity in heart failure: 
a community perspective. Am J Med. 2015; 128: 38-45.
16  Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and 
heart failure: a position statement from the Heart Failure Association of the Euro-
pean Society of Cardiology. Eur J Heart Fail. 2018; 20: 853-872.
17  Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart fail-
ure in type 2 diabetes: an update. Diabetes Care. 2004; 27: 1879-1884.
18  Ponikowski P, Voors AA, Anker SD, et al. Wytyczne ESC dotyczące diagnostyki 
i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol Pol. 2016; 
74: 1037-1147. (Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure: the Task Force for 
the diagnosis and treatment of acute and chronic heart failure of the European So-
ciety of Cardiology (ESC). Developed with the special contribution of the Heart Fail-
ure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129-2200.)
19  Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular out-
comes, and mortality in type 2 diabetes. N Engl J Med. 2015: 373: 2117-2128.
20  Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and 
renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644-657.
21  Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular out-
comes in type 2 diabetes. N Engl J Med. 2019; 380: 347-357.
22  McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with 
heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008.
23  Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with 
empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413-1424.
According to the Summary of Product Char-
acteristics, dapagliflozin should be adminis-
tered once daily at a dose of 10 mg. It can be 
taken at any time of the day, with or between 
meals. In T2D therapy, dapagliflozin can be used 
alone or in combination with other antidiabetic 
agents. It is crucial to effectively select patients 
for the treatment with dapagliflozin.
Dapagliflozin should be considered in:
•	 patients with HFrEF with left ventricular ejec-
tion fraction lower than or equal to 40%2 2
•	 patients with NYHA functional class II to IV22
•	 patients with or without T2D2 2,39
•	 patients on standard cardiovascular treat-
ment (ie, β-blocker and / or renin–angiotensin–
aldosterone system inhibitor [ACEI / ARB or 
ARNI], and MRA if recommended)2 2—dapa-
gliflozin can be added to any HF therapy2 2
•	 creatinine clearance should be greater than 
or equal to 30 ml/min/1.73 m229,32
Renal function should be assessed based on 
creatinine clearance according to the following 
schedule: before starting treatment with dapa-
gliflozin and at least annually thereafter; before 
the initiation of drugs that may interfere with 
kidney function, and then periodically through-
out treatment.
The use of dapagliflozin is beneficial while 
taking medications recommended for the treat-
ment of HFrEF. Dapagliflozin was shown to act 
synergistically with the drugs recommended 
by the HFrEF guidelines, regardless of the ther-
apy and target dose used.2 2 The clinically sig-
nificant observation showing that the effect of 
dapagliflozin was independent of the prima-
ry drug therapy supports the hypothesis that 
SGLT-2 inhibitors act in a mechanistically in-
dependent and complementary manner to other 
HFrEF therapies. Similarly, the dosing of the pri-
mary drug and the use of implantable devic-
es (eg, an implantable cardioverter-defibrilla-
tor or cardiac resynchronization therapy) do 
not alter the effect of dapagliflozin, suggesting 
an additional benefit regardless of optimized 
HFrEF pharmacotherapy or the use of thera-
peutic devices.
On October 15, 2020, the European Medicines 
Agency’s Committee for Medicinal Products for 
Human Use recommended dapagliflozin for ap-
proval for the indication of HF and, in November 
2020, dapagliflozin was approved in Europe (and 
therefore in Poland) to treat specifically adult 
patients with symptomatic chronic HFrEF.38,39
supplementaRy mateRial
The Polish version as well as the extended Polish version of the paper are available at 
www.mp.pl/kardiologiapolska.
aRticle infORmatiOn
cOnflict Of inteRest AS, AW, JD, JG, JK, JN,  and PL received lecture and 
consulting fees from AstraZeneca. AG received lecture honoraria. ML received 
lecture honoraria from AstraZeneca. EAJ and PP received lecture and consulting 
KARDIOLOGIA POLSKA 2021; 79 (3)370
24  Verma S, McMurray JJ V. SGLT2 inhibitors and mechanisms of cardiovascular 
benefit: a state-of-the-art review. Diabetologia. 2018; 61: 2108-2117.
25  Shimo N, Matsuoka T, Kaku K. Beneficial effects of sodium – glucose cotrans-
porter 2 inhibitors for preservation of pancreatic β-cell function and reduction of 
insulin resistance. J Diabetes. 2017; 9: 219-225.
26  Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 
inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, 
potential mechanisms, and clinical applications. Circulation. 2016; 134: 752-772.
27  Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects 
of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94: 26-39.
28  Tamargo J. Sodium-glucose cotransporter 2 inhibitors in heart failure: po-
tential mechanisms of action, adverse effects and future developments. Eur Car-
diol Rev. 2019; 14: 23.
29  Cosentino F, Grant PJ, Aboyans V, et al. Wytyczne Europejskiego Towarzystwa 
Kardiologicznego dotyczące cukrzycy i stanu przedcukrzycowego współistniejących 
z chorobami sercowo- naczyniowymi opracowane we współpracy z Europejskim 
Towarzystwem Badań nad Cukrzycą (2019). Kardiol Pol. 2019: 7-81. (Cosentino F, 
Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and car-
diovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 
41: 255-323.)
30  Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 
2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295-2306.
31  Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart 
failure and mortality in type 2 diabetes mellitus. Circulation 2019; 139: 2528-2536.
32  McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of 
the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mor-
tality in patients with heart failure and reduced left ventricular ejection fraction 
(DAPA-HF). Eur J Heart Fail. 2019; 21: 665-675.
33  Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation 
of the Kansas City cardiomyopathy questionnaire: a new health status measure for 
heart failure. J Am Coll Cardiol. 2000; 35: 1245-1255.
34  Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symp-
toms, function, and quality of life in patients with heart failure and reduced ejec-
tion fraction: results from the DAPA-HF trial. Circulation. 2020; 141: 90-99.
35  Docherty KF, Jhund PS, Anand I, et al. Effect of dapagliflozin on outpatient 
worsening of patients with heart failure and reduced ejection fraction: a prespec-
ified analysis of DAPA-HF. Circulation. 2020; 142: 1623-1632.
36  Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients 
with chronic kidney disease. N Engl J Med. 2020; 383: 1436-1446.
37  Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol 
of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Dis-
ease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35: 
274-282.
38  FORXIGA 10 mg – Summary of Product Characteristics [in Polish]. 2020.
39  European Medicines Agency. Forxiga dapagliflozin. https://www.ema.euro-
pa.eu/en/medicines/human/EPAR/forxiga. Accessed November 9, 2020.
40  Seferović PM, Coats AJS, Ponikowski P, et al. European Society of Cardi-
ology/Heart Failure Association position paper on the role and safety of new 
glucose‐lowering drugs in patients with heart failure. Eur J Heart Fail. 2020; 22: 
196-213.
